Proven Pharmaceutical Executive Brings Over 30 Years of R&D Experienceto Supercharge the Company’s Next Phase of Growth Seasoned Biotechnology Leader Mike Varney, Ph. D., Appointed as Lead Independent Director of the Board SAN FRANCISCO, CALIFORNIA, FEBRUARY 18, 2025 – Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug […]
San Francisco, CA – April 2, 2024 – Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter. The landmark study applied AtomNet to 318 targets through collaborations […]
CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]
Recognized for innovation in powering small molecule drug discovery with AI, Atomwise among the Top-10 in Biotechnology category SAN FRANCISCO, Calif. — March 9, 2021 — Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company’s prestigious annual list of the World’s Most […]